RESPIRE: Respiratory Muscle Structure and Function in Mechanically Ventilated Patients and Long-term Outcomes

Sponsor
University Health Network, Toronto (Other)
Overall Status
Recruiting
CT.gov ID
NCT05857774
Collaborator
(none)
230
1
11.1
20.7

Study Details

Study Description

Brief Summary

Air is normally pumped in and out of the lungs by the muscles that contribute to inhalation and exhalation, called the respiratory muscles. The abdominal muscles help by forcing air out of your lungs during exhalation; whereas the diaphragm, the main muscle used for breathing, contracts to get air into the lungs during inhalation. With mechanical ventilation, respiratory muscles are able to rest and recover while the breathing machine takes over; however, this may cause respiratory muscle weakness. Patients who develop weakness of these muscles may require more assistance from the ventilator and take longer to recover their ability to breathe without assistance. The impact of this phenomenon on long-term outcomes is uncertain.

The RESPIRE study is designed to characterize how respiratory muscles change during mechanical ventilation and to evaluate the impact on long term quality of life. An additional objective of this study is to examine novel measures obtained from automated functions of a ventilator, that may better predict success from weaning from mechanical ventilation.

Condition or Disease Intervention/Treatment Phase
  • Other: Sonographic measurements
  • Other: Physiological measurements
  • Other: Biological measurements

Detailed Description

Previous work has established that diaphragm atrophy during mechanical ventilation is associated with adverse clinical outcomes. Abdominal muscles, which are engaged during breathing also undergo atrophy during mechanical ventilation. However, the relationship between these muscles and how they relate to long term function status is known and warrants further investigation.

Mechanical ventilation is a life-saving technique in patients with respiratory failure, however reasons why some patients require long term ventilation and are unsuccessful from weaning from ventilators are not fully elucidated. Respiratory muscle dysfunction as a result of mechanical ventilation is only recently being understood. Diaphragm atrophy is associated with adverse clinical outcomes, but the same is unknown if this holds true with abdominal muscle atrophy. Properly understanding the natural progression of diaphragm and abdominal muscle atrophy and dysfunction, and how they relate to each other, is critical to identifying markers or factors that may put particular patients at risk for long durations of mechanical ventilation and adverse clinical outcomes.

This study will provide important insights into the relationship between inspiratory and expiratory muscle function, and the evolution of functional impairments in critical care patients undergoing weaning from invasive mechanical ventilation. Further understanding of the pathophysiological processes of how these muscle groups interact in this context is important in moving forward with potential therapeutic strategies aimed at mitigating injury.

Study Design

Study Type:
Observational
Anticipated Enrollment :
230 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Respiratory Muscle Structure and Function in Mechanically Ventilated Patients and Long-term Outcomes
Actual Study Start Date :
Apr 27, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Cases

Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation

Other: Sonographic measurements
Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Other: Physiological measurements
Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Other: Biological measurements
Skeletal troponin-I

Control condition A

Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation

Other: Sonographic measurements
Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Other: Physiological measurements
Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Other: Biological measurements
Skeletal troponin-I

Control condition B

Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula

Other: Sonographic measurements
Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

Other: Physiological measurements
Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

Other: Biological measurements
Skeletal troponin-I

Outcome Measures

Primary Outcome Measures

  1. Quality of life at home [Day 180]

    5-level EQ-5D (EQ-5D-5L) score - The EQ-5D-5L is a validated self-reported instrument assessing quality of life at the moment questionnaire is completed. Each question is scored from 1 (no problems) to 5 (inability to perform activity) and are independently assessed.

  2. Quality of life at home [Day 180]

    Montreal Cognitive Assessment (MOCA) score - MoCA is a clinician-reported measure to assess for cognitive impairments. MoCA is scored out of 30 with scores <26 indicating cognitive impairment.

Secondary Outcome Measures

  1. Duration of ventilation [Until hospital discharge (up to 6 months)]

  2. Muscle research council score [Until day 14]

    Muscle research council score, is a validated measure of muscle strength. Possible scores range from 0 (complete paralysis) to 60 (normal strength). Assessments will be made at first spontaneous breathing trial & at day 14.

  3. Airway occlusion pressure (P0.1) [First spontaneous breathing trial (within 5 minutes of onset)]

    P0.1 will be assessed during spontaneous breathing trial. Spontaneous breathing trials (SBT) are standard of care to assess if patients are able to be extubated from mechanical ventilation. A specific time frame cannot be provided as SBT are only conducted when care team deem the patient as capable.

  4. Expiratory occlusion pressure (Pocc) [First spontaneous breathing trial (within 5 minutes of onset)]

    Pocc will be assessed during spontaneous breathing trial. Spontaneous breathing trials (SBT) are standard of care to assess if patients are able to be extubated from mechanical ventilation. A specific time frame cannot be provided as SBT are only conducted when care team deem the patient as capable.

  5. Maximal inspiratory pressure (MIP) [First spontaneous breathing trial within 30 minutes of onset]

    MIP will be assessed during spontaneous breathing trial. Spontaneous breathing trials (SBT) are standard of care to assess if patients are able to be extubated from mechanical ventilation. A specific time frame cannot be provided as SBT are only conducted when care team deem the patient as capable.

  6. Days alive and at home at 180 days post ICU discharge [Day 180]

  7. Changes in abdominal muscle thickening fraction during cough [At first spontaneous breathing trial within 30 minutes of onset and at ICU discharge, an average of 7 days]

    Abdominal muscle thickening fraction during cough will be assessed by ultrasound during SBT when care team deems patient capable and safe to do so, as such a specific time frame for SBT cannot be provided. Additionally abdominal muscle thickening fraction will be assessed at ICU discharge. A specific time frame cannot be provided as ICU discharge will vary between patients.

  8. Maximal diaphragm thickening fraction [At first spontaneous breathing trial within 30 minutes of onset and at ICU discharge, an average of 7 days]

    Maximal diaphragm thickening fraction will be assessed by ultrasound during SBT when care team deems patient capable and safe to do so, as such a specific time frame for SBT cannot be provided. Additionally abdominal muscle thickening fraction will be assessed at ICU discharge. A specific time frame cannot be provided as ICU discharge will vary between patients.

  9. Changes in resting abdominal muscle thickening [Until Day 14]

    Diaphragm ultrasound to measure thickening of abdominal muscles during resting tidal breathing.

  10. Changes in resting thickening fraction [Until Day 14]

    Diaphragm ultrasound to measure thickening fraction during resting tidal breathing.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Cases Inclusion Criteria:

• Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation

Control condition A Inclusion Criteria:

• Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation

Control condition B Inclusion Criteria

• Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula

Exclusion Criteria:
  • Patients expected to be extubated within 24 hours of screening for eligibility

  • Patients who have already undergone a SBT at time of screening

  • Patients with a previously diagnosed neuromuscular disorder

  • Patients receiving long-term invasive mechanical ventilation (prior to current hospitalization)

  • Patients who have required previously (during current hospitalization) a period of invasive ventilation in ICU of more than 24 hours

  • Patients who have previously been enrolled in the study

  • Patients for whom post-hospital follow-up may be challenging, e.g. those who reside overseas or who have no fixed address

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toronto General Hospital Toronto Ontario Canada M5G 2N2

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Ewan Goligher, MD, PhD, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT05857774
Other Study ID Numbers:
  • 22-5875
First Posted:
May 15, 2023
Last Update Posted:
May 15, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 15, 2023